The projected costs and benefits of a supervised injection facility in Seattle, WA, USA.


Journal

The International journal on drug policy
ISSN: 1873-4758
Titre abrégé: Int J Drug Policy
Pays: Netherlands
ID NLM: 9014759

Informations de publication

Date de publication:
05 2019
Historique:
received: 22 05 2018
revised: 06 12 2018
accepted: 30 12 2018
pubmed: 26 2 2019
medline: 29 2 2020
entrez: 26 2 2019
Statut: ppublish

Résumé

As one strategy to improve the health and survival of people who inject drugs, the King County Heroin & Opioid Addiction Task Force recommended the establishment of supervised injection facilities (SIF) where people can inject drugs in a safe and hygienic environment with clinical supervision. Analyses for other sites have found them to be cost-effective, but it is not clear whether these findings are transferable to other settings. We utilized local estimates and other data sources deemed appropriate for our setting to implement a mathematical model that assesses the impact of a hypothetical SIF on overdose deaths, non-fatal overdose health service utilization, skin and soft tissue infections, bacterial infections, viral infections, and enrollment in medication assisted treatment (MAT). We estimated the costs and savings that would occur on an annual basis for a small-scale pilot site given current overdose rates, as well as three other scenarios of varying scale and underlying overdose rates. Assuming current overdose rates, a hypothetical Seattle SIF in a pilot phase is projected to annually reverse 167 overdoses and prevent 6 overdose deaths, 45 hospitalizations, 90 emergency department visits, and 92 emergency medical service deployments. Additionally, the site would facilitate the enrollment of 41 SIF clients in medication assisted treatment programs. These health benefits correspond to a monetary value of $5,156,019. The annual estimated cost of running the SIF is $1,222,332. The corresponding cost-benefit ratio suggests that the pilot SIF would generate $4.22 for every dollar spent on SIF operational costs. The pilot SIF is projected to save the healthcare system $534,453. If Seattle experienced elevated overdose rates and Seattle SIF program were scaled up, the health benefits and financial value would be considerably greater. This analysis suggests that a SIF program in Seattle would save lives and result in considerable health benefits and cost savings.

Sections du résumé

BACKGROUND
As one strategy to improve the health and survival of people who inject drugs, the King County Heroin & Opioid Addiction Task Force recommended the establishment of supervised injection facilities (SIF) where people can inject drugs in a safe and hygienic environment with clinical supervision. Analyses for other sites have found them to be cost-effective, but it is not clear whether these findings are transferable to other settings.
METHODS
We utilized local estimates and other data sources deemed appropriate for our setting to implement a mathematical model that assesses the impact of a hypothetical SIF on overdose deaths, non-fatal overdose health service utilization, skin and soft tissue infections, bacterial infections, viral infections, and enrollment in medication assisted treatment (MAT). We estimated the costs and savings that would occur on an annual basis for a small-scale pilot site given current overdose rates, as well as three other scenarios of varying scale and underlying overdose rates.
RESULTS
Assuming current overdose rates, a hypothetical Seattle SIF in a pilot phase is projected to annually reverse 167 overdoses and prevent 6 overdose deaths, 45 hospitalizations, 90 emergency department visits, and 92 emergency medical service deployments. Additionally, the site would facilitate the enrollment of 41 SIF clients in medication assisted treatment programs. These health benefits correspond to a monetary value of $5,156,019. The annual estimated cost of running the SIF is $1,222,332. The corresponding cost-benefit ratio suggests that the pilot SIF would generate $4.22 for every dollar spent on SIF operational costs. The pilot SIF is projected to save the healthcare system $534,453. If Seattle experienced elevated overdose rates and Seattle SIF program were scaled up, the health benefits and financial value would be considerably greater.
CONCLUSION
This analysis suggests that a SIF program in Seattle would save lives and result in considerable health benefits and cost savings.

Identifiants

pubmed: 30802842
pii: S0955-3959(19)30002-7
doi: 10.1016/j.drugpo.2018.12.015
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

9-18

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

J E Hood (JE)

Public Health - Seattle & King County, 401 Fifth Avenue, Suite 1250, Seattle, WA, United States. Electronic address: julia.hood@kingcounty.gov.

C N Behrends (CN)

Weill Cornell Medical College, 1300 York Ave. Box 65, New York, NY, 10065, United States.

A Irwin (A)

Law Enforcement Action Partnership, Silver Spring, MD, United States.

B R Schackman (BR)

Weill Cornell Medical College, 1300 York Ave. Box 65, New York, NY, 10065, United States.

D Chan (D)

King County Department of Community and Health Services, 401 Fifth Avenue, Suite 500, Seattle, WA, United States; University of Washington, School of Public Health, 1959 NE Pacific St, Seattle, WA, 98195, United States.

K Hartfield (K)

Public Health - Seattle & King County, 401 Fifth Avenue, Suite 1250, Seattle, WA, United States.

J Hess (J)

University of Washington, School of Medicine, 1959 NE Pacific St, Seattle, WA, 98195, United States.

C Banta-Green (C)

University of Washington, School of Public Health, 1959 NE Pacific St, Seattle, WA, 98195, United States.

L Whiteside (L)

University of Washington, School of Medicine, 1959 NE Pacific St, Seattle, WA, 98195, United States.

B Finegood (B)

King County Department of Community and Health Services, 401 Fifth Avenue, Suite 500, Seattle, WA, United States.

J Duchin (J)

Public Health - Seattle & King County, 401 Fifth Avenue, Suite 1250, Seattle, WA, United States; University of Washington, School of Public Health, 1959 NE Pacific St, Seattle, WA, 98195, United States; University of Washington, School of Medicine, 1959 NE Pacific St, Seattle, WA, 98195, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH